Free PDF Download

Total Page:16

File Type:pdf, Size:1020Kb

Free PDF Download Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2016; 20: 339-344 Effect of bedtime dosing of barnidipine hydrochloride in non-dipper hypertensive patients with obstructive sleep apnoea not treated with continuous positive airway pressure G. CRIPPA, D. ZABZUNI, A. CASSI, E. BRAVI Department of Internal Medicine, Hypertension Unit, Guglielmo Da Saliceto Hospital, Piacenza, Italy Abstract. – OBJECTIVE: Obstructive sleep ap - Abbreviations noea (OSA) is considered a cause of secondary hypertension. About 50% of patients with OSA show elevated blood pressure levels. Non-dipper OSA = obstructive sleep apnoea; CPAP = continuous pattern (blunted or absent nocturnal decrease of positive airway pressure; ABP = Ambulatory blood pres - blood pressure) is frequently observed in patients sure ; CCB = calcium channel blocker . with OSA and is associated with increased cere - bral, cardiovascular and renal events. The aim of this study was to observe the effect of barnidipine calcium channel blocker on these patients. Introduction PATIENTS AND METHODS: Forty-one pa - tients (mean age 69 ± 17 years, 18 females) with Obstructive sleep apnoea ( OSA) syndrome is a previously diagnosed OSA (by reduced channel common condition affecting around 5% of the gen - home-based polysomnography) who were not eral population. It is consistently more prevalent in being treated with continuous positive airway 1-2 pressure (CPAP) because of contraindications males with a male to female ratio of up to 8:1 . or because of patient intolerance or rejection The association between OSA and hyperten - were evaluated. Non-dipper status was defined sion is well documented. Scientific data and clin - as the presence of a nighttime fall in systolic ical awareness regarding the interaction between blood pressure (BP) which was < 10% that of OSA and hypertension are continuously increas - daytime systolic BP as observed in a previous ing 3. Approximately 50% of patients with OSA ambulatory blood pressure (ABP) monitoring. OSA was defined according to the presence of are hypertensive, and an estimated 40% of hyper - 4-6 5 or more episodes per hour of apnoea, hypop - tensive patients have OSA . noea or arousal due to respiratory effort. The prevalence of hypertension in OSA syn - The reproducibility of non-dipping status was drome appears to be influenced by the severity of confirmed through a second 24-h ABP monitor - the breathing disorder. In patients with OSA an ing performed at baseline. On top of the previ - ous stable treatment regimen (which excluded augmented sympathetic activity at rest, which per - calcium-channel blockers), a 10 mg dosing of sists not only during the apneas, has been ob - barnidipine hydrochloride at bedtime was added served . The increased sympathetic tone affects to all subjects during a 12-week period. vascular resistance, cardiac output, and renin-an - RESULTS: Among the 41 non-dipper patients, giotensin-aldosterone system activity. These 32 (78%) showed complete normalization of cir - changes play an essential role in the genesis of the cadian rhythm. Add-on treatment with barnidip - ine was generally well tolerated. organism’s acute and chronic responses, and part - CONCLUSIONS: Bedtime dosing of the calci - ly explain the pathophysiological mechanisms be - um-channel blocker (CCB) barnidipine signifi - hind the chronic cardiovascular consequences re - cantly reduced mean nighttime systolic and di - lated to OSAS, and in particular hypertension 7-11 . astolic ABP in hypertensive patients presenting One of the characteristics of hypertensive pa - with non-dipper pattern and OSA – not on CPAP tients with OSA is the blunted nocturnal decline treatment. Moreover, it restored the previously 3,12-14 altered circadian rhythm in the majority of them. in blood pressure (non-dipper pattern) . The specific relationship between non-dipper status Key Words: and the risk of cerebral, cardiovascular and renal Barnidipine hydrochloride, Non-dipper pattern, events is well established 15-18 . Therefore, the nor - Obstructive sleep apnoea, ABP monitoring. malization of the circadian BP rhythm should be Corresponding Author: Dorjan Zabzuni, MD; e-mail: [email protected] 339 G. Crippa, D. Zabzuni, A. Cassi, E. Bravi considered an important goal of antihypertensive The aim of our study was to evaluate the effect treatment. of an add-on bedtime dosing of barnidipine on A better lifestyle and dietary intervention the circadian rhythm of BP in non-dipper hyper - should always be considered as the first step in tensive patients with OSA, who were not being the treatment of patients with OSA. treated with CPAP because of contraindications Overweight/obesity and a sedentary lifestyle or patient intolerance or rejection . are very common in such patients , as well as al - Barnidipine hydrochloride is a safe, effective cohol and tobacco consumption. Thus, body and well tolerated dihydropyridine calcium chan - weight reduction, increased physical activity, nel blocker, available in a modified-release for - smoking cessation and alcohol intake reduction mulation, which has a gradual onset of action should be suggested to all apnoeic subjects, inde - and a sustained effect. Its antihypertensive action pendently of the presence of hypertension or oth - is mainly related to the reduction of peripheral er cardiovascular risk factors. vascular resistance 33 -36 . Other measures such as avoiding the supine position (lying on one’s back) during sleep in the event of positional OSA, the use of mandibular Patients and Methods advancement prosthesis (oral appliance) or, more rarely, surgery, have shown some positive effects In a post-hoc analysis of a larger observational in the management of OSA syndrome. However, study 37-38 , in which we evaluated the response to in terms of specific therapies, continuous posi - the add-on treatment with barnidipine in non-dip - tive airway pressure (CPAP) remains the refer - per hypertensive patients, we have analyzed the ence treatment for OSA. effect of this calcium-channel blocker in a subset Prospective cohort studies in patients with of patients with OSA. We considered 41 pharma - OSA syndrome have shown that treatment with cologically treated non-dipper hypertensive pa - CPAP significantly reduces the risk of cardiovas - tients (18 females, mean age 69 ± 17 years) with cular events in patients with severe OSA 19-22 . OSA and who were not being treated with CPAP. The effects of CPAP on BP have also been in - The evaluation of respiratory disorder was car - vestigated , but the results of these studies are ried out by using a reduced channel home-based sometimes divergent and not conclusive. Some device (Embletta X 100, Broomfield, CO, USA). studies show a beneficial effect with significant Overnight Polysmnography was evaluated by an systolic and diastolic BP reduction , while others experienced pulmonologist. show only a minor and non-significant reduction OSA was defined as the detection of 5 or more in BP 23-29 . symptomatic events per hour ( apnoea , hypop - Only a few studies have analyzed the varia - noea or arousal due to breathing effort) or 15 or tions in dipper/non-dipper profiles with CPAP more events per hour in the absence of reported treatment and their results are not homoge - symptoms. Patients with a central apnoea index neous 24-27 . above 5 were excluded. One of the concerns regarding CPAP treat - Non-dipper pattern was defined as the pres - ment is adherence to the therapy. When adher - ence of a nighttime fall in ambulatory systolic ence is defined as the use of CPAP for more than blood pressure which constituted less than 10 % 4 hours per night, 46 to 83% of apnoeic patients of daytime systolic blood pressure at baseline. have been reported as being non-adherent to Patients with symptomatic hypotension during treatment 30 ,31 . Furthermore, it is a common clini - the entire ABPM recording were excluded. cal observation that the proposal of CPAP treat - ABP monitoring was performed by using a non- ment is often rejected by many patients. invasive, portable validated recorder (SpaceLabs Regarding antihypertensive therapy , there is Inc. model 90207-30). Patients wore the device for no obvious antihypertensive drug class that has 24 hours on all days except holidays and the repeatedly demonstrated superior efficacy in recorder was set to take readings every 15 minutes OSA patients with hypertension 32 . during daytime (7 am to 11 pm) and every 30 min - However, the altered circadian rhythm that utes during nighttime (11 pm to 7 am) . may characterise apnoeic hypertensive individu - The analysis of ABP monitorings, the evalua - als, suggests that, the increased antihypertensive tion of daytime nighttime and circadian rhythm efficacy during nighttime could, at least theoreti - and the night-to-day BP ratio were performed ac - cally, reverse the non-dipper pattern. cording to the 2013 ESH-ESC guidelines 39 . 340 Barnidipine bedtime administration in non-dipper hypertensive patients with OSA ABP recording was considered complete when Results 80% or more of the scheduled readings were available , with at least 2 valid readings per hour. The study was completed in forty-one individ - Antihypertensive treatment included an - uals 41 with moderate-to-severe OSA , as well as giotensin-converting-enzyme inhibitors, early- hypertension with confirmed non-dipper pattern. distal-tubule diuretics, angiotensin-receptor All patients had mean daytime ABP values blockers and beta-adrenergic blockers , while pa - above 135/85 mmHg and mean nighttime ABP tients being treated with calcium-channel block - values above 120/70 mmHg. In all patients , the ers of any kind were excluded from the study. nocturnal systolic mean ABP fall resulted in less Before enrollment, all patients had been receiv - than 10% with respect to daytime mean values ing stable antihypertensive treatment during the (night-day BP ratio > 0.9). previous 2 months at least, without changes in Among the 41 patients, 9 of them showed a dosage or type of drug. riser pattern, with BP increasing rather than dip - All patients received a 10 mg dosing of barni - ping during the night.
Recommended publications
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Ep 0661045 B1
    Europäisches Patentamt *EP000661045B1* (19) European Patent Office Office européen des brevets (11) EP 0 661 045 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 9/22, A61K 47/34, of the grant of the patent: A61K 47/36, A61K 9/20 03.07.2002 Bulletin 2002/27 (86) International application number: (21) Application number: 93919648.1 PCT/JP93/01297 (22) Date of filing: 10.09.1993 (87) International publication number: WO 94/06414 (31.03.1994 Gazette 1994/08) (54) SUSTAINED-RELEASE HYDROGEL PREPARATION HYDROGELZUBEREITUNG MIT VERZÖGERTER FREISETZUNG PREPARATION D’HYDROGEL A LIBERATION PROLONGEE (84) Designated Contracting States: • SAWADA, Toyohiro AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT 12-14, Koishigawa-cho 3-chome SE Shizuoka 426 (JP) • OKADA, Akira 12-6, Izumi-cho (30) Priority: 18.09.1992 JP 27497992 Shizuoka 426 (JP) 08.06.1993 JP 16526393 • FUKUI, Muneo 13-14, Minamisurugadai 5-chome Shizuoka 426 (JP) (43) Date of publication of application: 05.07.1995 Bulletin 1995/27 (74) Representative: Geering, Keith Edwin REDDIE & GROSE (73) Proprietor: YAMANOUCHI PHARMACEUTICAL 16 Theobalds Road CO. LTD. London WC1X 8PL (GB) Tokyo 103 (JP) (56) References cited: (72) Inventors: EP-A- 0 067 671 JP-A- 3 002 119 • SAKO, Kazuhiro 7-7, Higashikogawa 4-chome JP-A- 3 034 927 JP-A- 4 217 924 Shizuoka 425 (JP) JP-A- 4 501 411 US-A- 4 968 508 • NAKASHIMA, Hiroshi 28-2, Mise Shizuoka 422 (JP) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Reversal Effects of Ca2+ Antagonists on Multidrug Resistance Via Down-Regulation of MDR1 Mrna
    Kobe J. Med. Sci., Vol. 53, No. 6, pp. 355-363, 2007 Reversal Effects of Ca2+ Antagonists on Multidrug Resistance via Down-regulation of MDR1 mRNA CHIHO KOMOTO1, TSUTOMU NAKAMURA1, 2, MOTOHIRO YAMAMORI1, NOBUKO OHMOTO1, HIRONAO KOBAYASHI3, AKIKO KUWAHARA1, KOHSHI NISHIGUCHI1, KOHJI TAKARA4, YUSUKE TANIGAWARA5, NOBORU OKAMURA2, KATSUHIKO OKUMURA1, 2 and TOSHIYUKI SAKAEDA1, 6 1 Department of Hospital Pharmacy, School of Medicine, Kobe University, Kobe 650-0017, Japan, 2 Department of Clinical Evaluation of Pharmacotherapy, Graduate School of Medicine, Kobe University, Kobe 650-0047, Japan, 3 Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka 553-0002, Japan, 4 Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan, 5 Department of Hospital Pharmacy, School of Medicine, Keio University, Tokyo 160-8582, Japan, 6 Center for Integrative Education of Pharmacy Frontier (Frontier Education Center), Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan Received 21 June 2007 /Accepted 10 September 2007 Key words: MDR1/P-glycoprotein, Ca2+ antagonist, multidrug resistance, down-regulation, mRNA expression In previous reports, the effects of 12 Ca2+ antagonists on a multidrug resistant transporter, P-glycoprotein/MDR1, were evaluated in terms of those on MDR1-mediated transport of [3H]digoxin and the sensitivity of vinblastine sulfate or paclitaxel, and they were able to be classified into 4 subgroups based on their actions, as those with transport inhibition and sensitivity recovery, those with or without transport inhibition but marginal sensitivity recovery, and those without both. In this study, our previous findings were confirmed by the resistance against doxorubicin hydrochloride and daunorubicin hydrochloride, and by the recovery of [3H] vinblastine sulfate accumulation.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • PDF-Document
    Table 1. Checklist for Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Reported on Section/topic # Checklist item page # TITLE Title 1 Identify the report as a systematic review, meta-analysis, or both. 1 ABSTRACT Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and Structured 2 interventions; study appraisal and synthesis methods; results; limitations; 1 summary conclusions and implications of key findings; systematic review registration number. INTRODUCTION Rationale 3 Describe the rationale for the review in the context of what is already known. 1-2 Provide an explicit statement of questions being addressed with reference to Objectives 4 participants, interventions, comparisons, outcomes, and study design 2 (PICOS). METHODS Indicate if a review protocol exists, if and where it can be accessed (e.g., Web Protocol and 5 address), and, if available, provide registration information including - registration registration number. Specify study characteristics (e.g., PICOS, length of follow-up) and report Eligibility criteria 6 characteristics (e.g., years considered, language, publication status) used as 2 criteria for eligibility, giving rationale. Describe all information sources (e.g., databases with dates of coverage, Information 7 contact with study authors to identify additional studies) in the search and 2 sources date last searched. Present full electronic search strategy for at least one database, including any Search 8 2 limits used, such that it could be repeated. State the process for selecting studies (i.e., screening, eligibility, included in Study selection 9 2-3 systematic review, and, if applicable, included in the meta-analysis). Describe method of data extraction from reports (e.g., piloted forms, Data collection 10 independently, in duplicate) and any processes for obtaining and confirming 3 process data from investigators.
    [Show full text]
  • Wo 2011/060944 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... _ 26 May 2011 (26.05.2011) WO 2011/060944 A2 (51) International Patent Classification: (74) Agents: CARVAJAL Y URQUIJO, Isabel et al; A61K 9/16 (2006.01) A61K 9/50 (2006.01) Clarke, Modet & Co., C/Goya 11, 28001 Madrid (ES). A61K 9/48 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP20 10/007024 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 19 November 2010 (19.1 1.2010) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Langi English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 200931026 20 November 2009 (20.1 1.2009) ES TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicants (for all designated States except US): GP (84) Designated States (unless otherwise indicated, for every PHARM, S.A. [ES/ES]; Poligono Industrial Els Vinyets- kind of regional protection available): ARIPO (BW, GH, Els Fogars, Ctra.
    [Show full text]